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A B S T R A C T
In circulation, sheddingofmicroparticles fromavarietyof viable cells canbe triggeredbypatho-
logicalactivationof inﬂammatoryprocesses,byactivationof coagulationorcomplementsystems,
or by physical stress. Elevatedmicroparticle content (MPC) in donor bloodmight therefore in-
dicate a clinical condition of the donor which, upon transfusion, might affect the recipient. In
blood products, elevated MPC might also represent product stress. Surprisingly, the MPC in
blood collected fromnormal blooddonors is highly variable,which raises thequestionwhether
donormicroparticles are present in-vivo and transfer into theﬁnal blood component, andhow
productionmethods andpost-productionprocessingmight affect theMPC.WemeasuredMPC
using ThromboLUX in (a) platelet-rich plasma (PRP) of 54 apheresis donors and the corre-
spondingapheresis products, (b) 651apheresis and646pooledplatelet concentrates (PCs)with
plasma and 414 apheresis PCs in platelet additive solution (PAS), and (c) apheresis PCs before
and after transportation, gamma irradiation, and pathogen inactivation (N = 8, 7, and 12 re-
spectively). ThromboLUX-measured MPC in donor PRP and their corresponding apheresis PC
samples were highly correlated (r = 0.82, P = .001). The averageMPC in pooled PC was slightly
lower than that in apheresis PC and substantially lower in apheresis PC storedwith PAS rather
thanplasma.Mirasol PathogenReduction treatment signiﬁcantly increasedMPCwithage. Thus,
MPCmeasured in donor samples might be a useful predictor of product stability, especially if
post-production processes are necessary.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Microparticles are an important factor in transfusion
medicine [1–3]. These small vesicles found in blood plasma
play complex and dynamic physiological roles as media-
tors of far-reaching intercellular communication by
expressing a variety of membrane-associated proteins and
by transferring receptors, growth factors, and microRNA
[1–4]. Microparticles can be markers of inﬂammation [4]
and hypercoagulation [3]. Microparticles are continuously
released from red blood cells, white blood cells, endothe-
lial cells, and platelets in response to epinephrine, ADP,
thrombin, collagen, and Ca2+ ionophore, or as a result of the
extracorporeal storage [1]. Seventy to ninety percent of
microparticles are derived from platelets [5,6]. Platelets, in
addition to responding to agonists, generate microparticles
in response to complement activation, shear forces, senes-
cence, and cytoskeletal abnormalities [2]. Increased
concentration or altered characteristics of plasma
microparticles in vivo are associated with hypertension [7],
cardiovascular disease [8], recurrent miscarriage [9],
transfusion-related acute lung injury [10], bacterial endo-
toxin [11], hypercoagulability in type 2 diabetes [12], Crohn’s
disease [13], sepsis [14,15], and auto-immune diseases such
as rheumatoid arthritis, psoriasis and asthma [16–18], and
melanoma [19]. In addition, the proportional increase of
microparticle content (MPC) relative to platelet concentra-
tion during storage of platelet concentrate (PC) can be
attributed to different methods of separation or varying pro-
cessing conditions [20].
In blood products, elevated MPC might therefore indi-
cate an undesirable condition in the donor that could affect
the recipient after product transfusion. In fresh platelet prod-
ucts, MPCmay indicate the level of stress that platelets were
exposed to in the donor or during product separation [1,21].
Consequently, high MPC in the transfused platelet product
could, for example, reduce platelet recovery by a direct effect
on the recipient’s immune system [1] or because the stress
that generated the microparticles in the donor, or during
product separation, marks the platelets for removal from
circulation [22,23]. In addition, storage lesion also gener-
ates microparticles with aging of the platelet product [1,3].
Microparticles may participate in endothelial and macro-
phage activation, which in turn may shorten the platelet life
span [24].
Surprisingly, theMPC in blood from normal healthy trans-
fusion donors is highly variable and affected by diet [25,26]
and exercise [27]. This observed variation raises the ques-
tion of the extent to which donor microparticles transfer
into the donated product and how production methods and
post-production processing might affect the MPC. One im-
munocytochemistry study describes the carryover of donor
microparticles into the apheresis product, where the
microparticles appear to bemainly harvested from the donor
[28]. Thus, MPC measured in donor samples might be a
useful predictor of blood product MPC and therefore product
stability.
Several technologies have been used and described in
the literature for themeasurement of microparticles in blood
and other body ﬂuids [1,21,24,29], including established
methods such as ﬂow cytometry and dynamic light scat-
tering [30]. The measurement principle of the ThromboLUX
microparticle assay is dynamic light scattering, which has
long been used in the pharmaceutical industry for quality
control of liposomal drugs, which are in the size range of
microparticles. Dynamic light scattering is ideally suited
for routine screening of particle content based on size but
not for functional characterization of these particles. The
special DLS setup in ThromboLUX also allows microparticle
enumeration to be performed in native platelet-rich plasma
and platelet concentrate samples, i.e., without removal of
platelets, which is essential for routine screening. The
ThromboLUX microparticle assay is validated as a measure
of MPC in pooled PC because it correlates highly with mea-
sures of microparticle concentration obtained by ﬂow
cytometry [31].
We hypothesized that the origin of microparticles in PCs
is the donor, and that post-production processing – such as
substitution of plasma with platelet additive solution (PAS),
transport, irradiation, or pathogen inactivation – can de-
crease or increase the MPC. Accordingly, we investigated the
relationship between the MPC of each donor’s platelet-
rich plasma (PRP) sample before apheresis and the MPC in
the donor’s corresponding apheresis PC. We chose apheresis
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product rather than pooled PC in order to obtain a one-to-
one comparison for each donor. In addition, to compareMPC
in different types of platelet products and post-production
conditions, we analyzed data sets obtained from two large
clinical studies and performed stress tests. To ﬁrst vali-
date the ThromboLUX microparticle assay for apheresis
PC, we performed an inter-device comparison with
ﬂow-cytometry.
2. Materials and methods
2.1. ThromboLUX-measured microparticle content
Analysis of dynamic light scattering and calculation of
the ThromboLUX score have been described elsewhere [30].
ThromboLUX (LightIntegra Technology Inc., Vancouver, BC,
Canada) measures themicroparticle contribution to the total
scattering intensity in the sample. The relative contribu-
tions of microparticles, platelets, and microaggregates to
the dynamic-light-scattering signal were determined and
particle size histogramswere obtained. Microparticle content
was shown in the particle size distribution as particles with
radii between 50 nm and 550 nm (Fig. 1A). Microparticle
content reﬂects the relative contribution or proportion of
microparticles compared to platelets and is therefore also
a function of the platelet concentration of the sample.
Accordingly, the absolute microparticle concentration
is calculated by multiplying the ThromboLUX-reported
microparticle factor by the platelet count obtained with a
hematology analyzer. Exosome-sized particles with radii
below 50 nm are also shown in the size distribution
(Fig. 1A)
A
B
C
microparticles
platelets
Fig. 1. Comparison of MPC in apheresis PC determined by ThromboLUX and ﬂow cytometry. (A) Example of ThromboLUX test results showing the con-
tribution of exosome-sized particles (radii below 50 nm), microparticles (radii 50–550 nm), platelets, andmicroaggregates (radii above 550 nm). The ThromboLUX
test consists of 3 sequential intensity measurements at 37 °C, 20 °C, and 37 °C. Scores are calculated for each measurement and averaged for the ﬁnal score.
(B) Example obtained with ﬂow cytometry of a scatter plot and histogram showing platelet and microparticle events. (C) Scatter plot showing high cor-
relation with ﬂow cytometry (r = 0.98, P < .0001, N = 71 samples). PLT, platelet; %, percent of area under the relative-intensity curve; MP, microparticle;
PDI, polydispersity index; gated MP %, gating by size.
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2.2. Flow cytometry
Standard ﬂow cytometers have manufacturer-
recommended detection limits within themicroparticle size
range of about 500 nm–1 μm. However, with certain in-
strument and parameter settings, the use of internal-
calibration ﬂow cytometry has been shown to adequately
measure microparticles [31–33]. For internal calibration,
ﬂuorescently labeled polystyrene beads are added. Ten thou-
sand ﬂuorescently-labeled 1-μm polystyrene beads are
counted as ﬂuorescence events, providing normalization of
the platelet and microparticle counts, which are gated sep-
arately by their forward and side scatter. The percentage of
microparticles in a sample is calculated as the number
of gated microparticle events divided by the total number
of non-ﬂuorescent events (Fig. 1B).
Flow cytometry was performed on a FACSCanto II ﬂow
cytometer with FACSDiva software version 6.1.3 (BD Bio-
sciences, Becton, Dickinson and Company, San Jose, CA, USA).
Reagent solution of 0.2% formaldehyde in normal saline was
prepared by dissolving 9.00 g of sodium chloride in 1000ml
of distilled water, then adding 5.4 ml of 37% formalde-
hyde stock, mixing, and storing in a closed container at room
temperature. Microspheres (Flouresbrite Carboxylate YG 1.0-
μm yellow-green, Polysciences Inc., Warrington, PA, USA)
were diluted 1 in 200 in distilled water (Gibco Life Tech-
nologies Inc., Burlington, ON, Canada). The PC was sampled
in a laminar ﬂow cabinet using aseptic technique. Flow
cytometry settings were as follows. FSC-H: 700 V, SSC-H:
400 V, FL1 PMT: 320 V, threshold (FSC and SSC): 200, ﬂow
rate: low, bi-exponential display: ON.
2.3. Sample preparation
All blood products were collected with informed consent
from healthy volunteer donors under an institutionally ap-
proved human use protocol. Collection, processing, and
storage followed United States Food and Drug Administra-
tion (FDA) and American Association of Blood Banks (AABB)
guidelines.
To compare MPC measured with ThromboLUX and ﬂow
cytometry, 40 apheresis PCs (Trima Accel, Terumo BCT, Lake-
wood, CO, USA) were collected over a period of 10 weeks
and tested on day 1 of storage. Thirty one of these PCs were
also tested on day 5 of storage (N = 71).
Donor PRP was obtained from 54 apheresis donors to
evaluate ThromboLUX for donor testing before the produc-
tion of apheresis concentrates. Fresh EDTA anticoagulated
whole blood samples were obtained. PRP was obtained by
centrifuging at 150 g (depending on the centrifuge and rotor
this might be 800–1100 rev min−1) for 12 minutes at 22–
24 °C. The supernatant PRP was collected with a plastic
transfer pipette into a microcentrifuge tube or equivalent
container and kept on themixer. The capillary was ﬁlledwith
100 μl of the sample following the ThromboLUX Test Kit in-
structions for use. PRP was analyzed on the ThromboLUX
according to the Operator’s Manual. Each sample was tested
in duplicate. The corresponding donor apheresis PCs were
obtained using a Trima Accel (Terumo BCT, Lakewood, CO,
USA).
To compare different types of platelet products, the MPC
of 1711 platelet products was measured over the course of
two large clinical studies conducted in hospitals in Van-
couver (961 samples) and New York (750 samples). In
Vancouver, a large ThromboLUX data set from apheresis PC
(Trima Accel, Terumo BCT, Lakewood, CO, USA) and buffy-
coat pooled PC (platelets from four whole blood donors
pooled with the plasma of one of the four donors) was gath-
ered at the Vancouver General Hospital in 2010–2014.
Samples were obtained aseptically from PC before they were
transfused to hematology–oncology patients.
In New York, MPC in apheresis PC with either plasma or
PAS as suspension media was determined before transfu-
sion to oncology patients. A large data set was collected from
apheresis PC sampled prior to being sent from the blood
bank at North Shore University Hospital, 300 Community
Drive, Manhasset, NY 11030 to the Monter Center for trans-
fusion. At the blood bank it is routine practice to retain a
sample, in an FDA-cleared Fenwal blood storage pack (20ml
PVC plastic), from any platelet component immediately prior
to transfusion for availability for bacterial screening in the
event that a transfusion reaction is reported. Within 4 hours
of collection ThromboLUX testing was performed on a
surplus specimen of that sample at the Feinstein Institute
for Medical Research. The volume ratio of PAS and residu-
al plasma was 65:35. Machines used for apheresis collection
were the Amicus (Fenwal, Lake Zurich, IL, USA) for PAS con-
centrates and the Trima Accel (Terumo BCT, Lakewood, CO,
USA) for plasma concentrates. The mean microparticle con-
centration for platelet products was individually calculated
using the measured platelet counts (Sysmex XD 2100, Lin-
colnshire, IL, USA).
To test the effect of exposure to the stressors of gamma
irradiation and transport, sampleswere obtained from tubing
on the bag of the platelet apheresis concentrate (MCS+,
Haemonetics, Munich, Germany) after the tubing was
stripped three times with a manual stripping device. The
entire concentrate was agitated gently between each strip-
ping step to mix the content. Segments were removed from
the tubing by heat sealing and cutting an approximately
5-cm long piece. The top of the segment was cut open to
access the sample for aspiration into the ThromboLUX cap-
illary. Fifteen test samples of apheresis PCs were obtained
from 15 unique volunteer apheresis donors.
Samples were tested with ThromboLUX before and
after gamma irradiation with an IBL 437C irradiation
device using a Cesium-137 source and a center target
dose of 25 Gy (Gamma-Service Medical GmbH, Leipzig,
Germany) on day one after production (time difference of
4–8 hours, N = 8), as well as before and after simulated
transport (N = 7).
To test for the effect of exposure to the stressor of patho-
gen inactivation, apheresis platelet concentrates were
obtained from deferred normal volunteer donors at the Ca-
nadian Blood Services netCAD Research Donor Clinic. The
study protocol met the standards of the Declaration of Hel-
sinki and was approved by the Canadian Blood Services
ethics review committee. In accordance with the Declara-
tion of Helsinki, informed consent was obtained from all
donors. Apheresis platelet concentrates were prepared using
the Trima Accel (Terumo BCT, Lakewood, CO, USA) auto-
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mated blood collection system. Twelve double platelet
samples were collected, rested for a minimum of 2 h, then
divided into 2 equal components by weight. One compo-
nent was treated by the Mirasol Pathogen Reduction
Technology System (Terumo BCT, Lakewood, CO, USA): trans-
fer to a Mirasol storage bag, addition of 35 ml of riboﬂavin
solution, and exposure to a metered dose of UV light in the
Mirasol illuminator. The control component was trans-
ferred to a Mirasol storage bag and received 35ml of a 0.9%
saline solution, the same carrier solution that dissolves the
riboﬂavin, to ensure that both components had the same
platelet concentration. Components were sampled and tested
on days 1, 2, 5, and 7 post-collection.
2.4. Data analysis
Data analysis was aimed at determining the distribu-
tion of microparticles in PCs and the difference between
apheresis and pooled PCs in their relative and absoluteMPCs.
All statistical analysis was performed using Microsoft Excel
2013 and Minitab version 17.2.1. Pearson’s correlation co-
eﬃcients were calculated for bivariate regressions between
MPC in donor PRP and MPC in samples of corresponding
apheresis PC. Two-sample t-tests were performed for the
comparison of different types of platelet products. A P value
of <.05 was considered statistically signiﬁcant.
3. Results
3.1. Inter-device comparison of apheresis MPC measured by
ThromboLUX and ﬂow cytometry
ThromoLUX-measured MPC was highly correlated with
MPC enumerated by ﬂow cytometry in the same samples
of apheresis PCs (Fig. 1C; r = 0.98, P < .0001). Moreover, the
ratio of microparticles to intact platelets as measured by the
two devices was also very similar.
3.2. Prediction of apheresis product MPC by the MPC of the
donor’s PRP
Microparticle content in donor PRP samples was not nor-
mally distributed across donors (Fig. 2.). The apheresis
process, which enriches platelets, decreased the MPC in the
apheresis platelet product by an average of 75% (Fig. 3). In
this study, only 2% of apheresis products contained more
than 30% microparticles (Fig. 3).
Levels of microparticles in apheresis-donor PRP samples
were highly correlated with levels of microparticles in the
corresponding apheresis platelet donation immediately after
PC collection (Fig. 4). When donor MPC was high, MPC in
the corresponding apheresis PC tended to be high as well
(Fig. 5). In addition, the higher platelet count in the PC ne-
cessitates a proportionately lower relative MPC value in the
product of approximately 34% of the MPC in the donor PRP.
Accordingly, a linearmodel describes the relationship of MPC
in donor and product samples of this data set with the fol-
lowing equation:
Product MP Donor MP= − + ×0 01106 0 3388. .
3.3. Estimate of microparticle concentration from large trial
data sets
3.3.1. Vancouver General Hospital
The best ﬁt of the histogram data for the distribution of
microparticle concentration (particles ranging in radii from
50 to 550 nm) was obtained with a 3-parameter lognor-
mal distribution curve for both apheresis PCs and pooled
PCs. The mean microparticle concentrations in apheresis PC
in plasma and in pooled PC in plasma were 3.7 × 1012 l−1
[15.6 ± 11 (SD)%, 315 samples, 95% CI = 14–17%] and
3.2 × 1012 l−1 [21.1 ± 13 (SD)%, 646 samples, 95% CI = 20–
22%], respectively. These differences were signiﬁcant (P < .05).
The average platelet count for apheresis concentrates was
1.476 × 1012 platelets l−1 and for pooled PCs was 9.27 × 1011
platelets l−1. Thus, the mean MPC, which was proportional
to platelets, was signiﬁcantly higher (5.6%, P < .001) in pooled
Fig. 2. Histogram of MPC in donor PRP (bars) compared to best ﬁt
3-ParameterWeibull distribution (gray curve), showing that 33% of 54 donor
PRP samples contained more than 30% microparticles (gray shaded area).
The probability plot for MPC (N = 53) showed a mean of 20.6% and very
wide distribution with 5 and 95 percentiles of 4.4% and 68.2%.
Fig. 3. Histograms of MPC in 54 donor PRP (light bars) and the corre-
sponding apheresis PCs (overlapping dark bars). This data set for both PRP
and apheresis PC was best approximated by aWeibull distribution because
most donors had a very lowMPC. Enrichment of platelets in the apheresis
product is shown by the mean (50th percentile) MPC, which is 20.6% for
donor samples and only 5.1% for the corresponding product. MP,
microparticle.
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than apheresis concentrates. However, when taking the
much lower platelet count of pooled concentrates into
account, the mean microparticle concentration was lower
in pooled products compared to apheresis products.
The size distributions also showed that 62 of 315 (20%)
apheresis and 364 of 646 (56%) of pooled concentrates con-
tained detectable numbers of particles with radii below
50 nm. In addition, a higher content of these small par-
ticles (3–5% relative intensity detected with ThromboLUX)
was found only in pooled concentrates (n = 19). The mean
radius ± standard deviation for these populations was
7 ± 3 nm in both apheresis and pooled PCs.
3.3.2. New York
Table 1 compares MPC and microparticle concentra-
tion (for samples with known platelet count) in apheresis
PCs with either plasma (n = 336 or 98) or PAS (n = 414 or
133) as the suspension medium. The best ﬁt of the histo-
gram data for the distribution of MPC in samples with
plasma as the medium was obtained with a 2-parameter
exponential distribution curve as a probability plot. The prob-
ability plot for MPC showed a mean of 8.6% and a very wide
distribution (5 and 95 percentiles of 1.1% and 35.3%) re-
ﬂecting the variability of MPC in plasma-containing PC. In
contrast, the best ﬁt for MPC from PCs with PAS as the
mediumwas obtained with a lognormal distribution curve.
Here the probability plot for MPC showed a mean of 6.1%
with a narrower distribution (5 and 95 percentiles of 1.3%
and 28.3%) indicative of lower variability of MPC in PAS-
containing PC. The mean microparticle concentration and
distribution of microparticles in PASwere substantially lower
than those in plasma products (MPC only reduced to 78%,
MP concentration reduced to 42%, Table 1.
Particles with radii below 50 nm were detected in 264
of 336 (79%) of plasma-containing PC and 49 of 414 (12%)
Fig. 4. Regression scatter plot for MPC for all particles with radii in the
range of 50–550 nm in 54 donor PRP compared to samples from the cor-
responding apheresis product; r = 0.82, P = .001. MP, microparticle.
A B
C
Fig. 5. Effect of post-production processes on MPC of platelet concentrates. Means of MPC in apheresis concentrates with plasma did not change signiﬁ-
cantly with transport in 8 samples (A), gamma irradiation in 7 samples (B), or pathogen inactivation with Mirasol in 12 samples compared to control on
the day of production (C, gray symbols are day 0). On day 7 of storage the means of MP concentrations in control and Mirasol-treated concentrates (C)
were very signiﬁcantly different (control 3.5 ± 3.2 × 1012 l−1, Mirasol-treated 5.6 ± 5.0 × 1012 l−1, P = .003).
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of PAS-containing PC with average contributions to the
ThromboLUX-measured relative intensity of only 1%. The
mean radii ± standard deviations for these populations were
11.3 ± 5 nm for plasma and 15.6 ± 5 nm for PAS products,
respectively.
3.4. Effect of post-production stressors on microparticle
content
3.4.1. Gamma irradiation and transport
No signiﬁcant effect was found in these small samples
(7 and 8, respectively).
3.4.2. Mirasol pathogen reduction
The difference between means for microparticle con-
centration in apheresis PCs with or without Mirasol
treatment was highly signiﬁcant (P = .003) on days 5 and
7 compared to controls. On day 7 the mean increase in MP
concentration in the Mirasol arm was 2.2 × 1012 l−1 (95%
CI = 0.9–3.4 × 1012 l−1). The changes were correlated with the
level of initial concentration.
4. Discussion
Our results indicate that the origin of microparticles in
apheresis PCs immediately after separation is the donor, and
that the type of product, the suspension medium, and post-
production pathogen-inactivation alter the MPC. Evidence
for the donor origin of microparticles is that the MPC of
donor PRP samples before apheresis was highly correlated
with the MPC in the donor’s corresponding apheresis PC.
Evidence for product and post-production differences is
(a) the platelet concentrate MPC data sets from two large
clinical trials showing that the mean microparticle concen-
tration was lower in pooled products compared to apheresis
product, (b) the ﬁnding that mean microparticle concen-
tration in PAS was substantially lower than that in plasma
products, and (c) the ﬁnding that Mirasol treatment in com-
bination with 5 or more days of storage increased MPC.
Because apheresis concentrates in PAS have only 35%
plasma left, it was expected that PAS products would contain
much fewermicroparticles than plasma products, as we have
found. Surprisingly, despite the removal of microparticles
with 65% of the plasma and replacement of that volumewith
microparticle-free PAS, the PCs with PAS showed an MPC
– the ratio of microparticles to platelets – that was similar
to PCs with plasma. This unexpectedly high percentage of
MPC was caused by the loss of platelets, which was unex-
pected. For the calculation of the actual concentration, the
true platelet count was used and therefore showed a much
lower concentration, as expected. It follows that our ﬁnd-
ings might explain the lower frequency of adverse reactions
in recipients of PAS compared to plasma product [34]
because of the substantially lower content in microparticles,
which have been reported to be inﬂammatory markers.
ThromboLUX-generated data contain information on the
content of smaller, exosome-sized particles with radii below
50 nm. These are very different particle populations than
microparticles and could comprise proteins or protein ag-
gregates as well as exosomes which are derived from
different cellular pathways, probably containing different
cargoes and having different effects than microparticles.
Further research is warranted to determine why the het-
erogeneity of these small particles was greater in pooled
compared to apheresis products in Vancouver and what the
source of the mean size and overall concentration differ-
ences seen between Vancouver and New York might be.
Although our pilot study of stressors on apheresis PC
from 7 to 8 donors showed no effect on MPC by simulated
transportation or gamma irradiation, more extensive studies
on post-production processing effects on MPC are
recommended.
Further evidence that MPC in transfusion-product re-
cipients can limit the effectiveness of platelet transfusion
in a clinically important way has been found in a recent
study by our group (unpublished results). In this study,
ThromboLUX-measured microparticle content was in-
versely correlated with recovery of radiolabeled fresh donor
platelets after reinfusion (r = −0.50, P = .001). In addition,
other studies suggest that high MPC has a negative effect
on transfusion outcome of prophylactic transfusions [21,24].
However, the pro-coagulant activity of microparticles might
be beneﬁcial in therapeutic applications to stop heavy bleed-
ing. Thus, screening platelet concentrates for high and low
MPCs may be helpful for targeted use of donor-to-patient
matched platelet concentrates depending on the application.
A question that arises is whether donor MPC is stable
over time in apheresis donors who donate regularly. Con-
sidering that microparticles were described as markers of
inﬂammation [4], donors might be stable with highMPC due
to chronic conditions (for example with asthma, allergies,
or high interleukins) or might not be stable (for example,
a window period of infection, or other transient condi-
tion). During the study reported here, some donors were
tested up to 3 times, and we found that some changed and
some did not. An interesting future study would be to collect
additional information from the donor to ﬁnd out why they
have “chronic” or “transient” high MPC.
Table 1
Comparison of relative MPC and microparticle concentration (calculated for product with known platelet count) in apheresis PCs with plasma or PAS sus-
pension medium tested in New York.
Plasma MPC % PAS MPC % Plasma microparticle × 1012 l−1 PAS microparticle × 1012 l−1
Sample size 336 414 98 133
Mean MPC 12.1 9.5 3.3 1.4
95% CIa 10.8–13.4 8.5–10.6 2.6–3.9 1.2–1.6
Standard deviationa 8 11 3.2 1.3
Difference between meansa 2.6 (P = .002) 1.9 (P < .0001)
a Assuming a normal distribution of data.
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Monitoring the MPC content of blood products could
allow interventions such as nanoparticle ﬁltering. Filter-
ing of plasmawith a nanoﬁlter of 75 nm greatly reducesMPC
and decreases thrombin generation in vitro without affect-
ing the protein content or the activity of coagulation factors
[29]. Nanoﬁltering might therefore make it possible to
remove microparticles from plasma that is returned to the
donor during apheresis collection to beneﬁt the donor as
well as the PC recipient.
Flow cytometry faces limitations with regard to detec-
tion limits for small size and the standardization of methods,
which are not relevant to the ThromboLUX assay [35–38].
Furthermore, ﬂow cytometry is not suitable for routine
quantitation of microparticles in PCs because this tech-
nique requires sophisticated and expensive instrumentation,
highly trained personnel to perform the test and interpret
the results, and several steps of sample preparation. In con-
trast, ThromboLUX does not require sample preparation and
determines microparticle content automatically. However,
ﬂow cytometry, which is based on the detection of specif-
ic binding of ﬂuorescently labeled antibodies, can be used
to identify the cellular origin and potential function of
microparticles. In this light, ThromboLUX and ﬂow cytometry
could be viewed as companion technologies where the
ThromboLUX assay is performed to quickly screen samples
for MPC and then ﬂow cytometry is used to subsequently
characterize the microparticles when the detected amount
warrants further investigation.
In conclusion, knowing thatMPC in the donor carries over
into the corresponding product and is altered during and
after production allows us to identify platelet products that
may be less viable or less resistant to post-production stress.
Therefore the ThromboLUX microparticle assay, vali-
dated as a measure of MPC in both apheresis and pooled
PC, could reduce the risk of ineffective transfusions.
Consequently, the complications associated with ineffec-
tive transfusions would be reduced. In the long-term,
characterizingMPC inplatelet products to gain improved clin-
ical effectiveness could dramatically lower the cost of platelet
transfusion therapy for hospitals and healthcare systems.
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